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Abstract. Bushen Huayu extract (BSHY), a traditional Chinese 
medicine, has been demonstrated to treat postmenopausal 
osteoporosis, however, the underlying mechanism remains 
to be fully elucidated. The aim of the present study was to 
investigate the therapeutic effect of BSHY and the mecha-
nisms underlying this effect in an in vivo postmenopausal 
osteoporosis animal model. A total of 1 g BSHY containing 
7.12 µg icariin was prepared. Low-dose BSHY (BSHY-L; 
11.1 g/kg), medium-dose BSHY (BSHY-M; 22.2 g/kg) and 
high-dose BSHY (BSHY-H; 44.4 g/kg) was administered to 
oophorectomized rats using intragastric infusion. Estradiol 
(E2), interleukin-6 (IL-6) and serum alkaline phosphatase 
(ALP) levels, as well as bone density, were determined. It 
was found that the levels of serum ALP in the BSHY-L, 
BSHY-M and BSHY-H groups (197.75±41.74, 166.63±44.83 
and 165.63±44.90 IU/l, respectively) were significantly 
decreased compared with the model group (299.13±45.79 IU/l; 
P<0.05), whilst the levels of E2 (16.89±1.71, 17.95±1.40 and 
18.34±1.43 pg/ml, respectively) increased compared with the 
model group (14.54±1.61; P<0.05). In addition, the levels of 
IL-6 decreased in the BSHY-L, BSHY-M and BSHY-H groups 
(91.85±14.81, 82.99±15.65 and 80.54±14.61 pg/ml, respectively) 
compared with the model group (105.93±16.50 pg/ml; P<0.05). 
Furthermore, it was demonstrated that BSHY increased the 
bone density in the BSHY-L, BSHY-M and BSHY-H groups 
(0.20±0.014, 0.22±0.016 and 0.22±0.017 g/cm2, respectively) 
compared with the model group (0.19±0.011 g/cm2; P<0.05). 
BSHY was also found to increase the number of osteoblasts 
in the BSHY-L, BSHY-M and BSHY-H groups (25.38±2.17, 
29.25±2.12 and 30.00±2.39, respectively), compared with in the 
model group (14.75±2.38; P<0.05), and decrease the number 
of osteoclasts in the BSHY-L, BSHY-M and BSHY-H groups 
(4.00±1.85, 4.25±1.39 and 5.75±1.49, respectively) compared 
with 9.50±1.60 observed in the model group (P<0.05). These 
results suggest that BSHY is a potential therapeutic drug for 
the treatment of osteoporosis in vivo. Furthermore, these results 
suggest that the mechanism by which BSHY decreases the 
serum levels of IL-6 may be by regulating E2.
Introduction
Postmenopausal osteoporosis is a type of systemic bone disease, 
characterized by a reduction in bone density, degradation of 
bone microstructure and an alteration in serum markers of 
bone metabolism, including alkaline phosphatase (ALP), estra-
diol (E2) and interleukin-6 (IL-6) in postmenopausal females. 
This results in bone fragility and an increased risk of fracture. 
Approximately a third of postmenopausal females suffer from 
osteoporosis and this is usually due to the marked reduction in 
estrogen levels (1). Hormone replacement therapy (HRT) has 
been demonstrated to prevent bone loss and commonly includes 
a combination of estrogen, progesterone and progestin (2). 
However, long-term HRT results in adverse side effects, 
including hypocalcemia, worsening of renal impairment and 
osteonecrosis of the jaw (3), and therefore novel therapeutic 
strategies for the treatment of postmenopausal osteoporosis are 
required. Bushen Huayu (BSHY) is used in traditional Chinese 
medicine. It is based on the unique philosophy of Chinese 
medicine, namely Bu Shen Hua Yu (complementing the kidney 
system and resolving blood stasis). According to the theory of 
traditional Chinese medicine, BSHY is able to improve the 
function of the kidney system, strengthen bones, improve blood 
circulation and relieve pain (4). The aim of the present study 
was to investigate the therapeutic effects of BSHY on bone 
density and morphology, as well as on serum markers of bone 
metabolism in a postmenopausal osteoporosis animal model, 
and to investigate the underlying mechanisms.
Materials and methods
Drugs and reagents. All Chinese medicinal materials used 
in the present study were purchased from Hubei Shennong 
Bencao Prepared Herbal Medicines Co., Ltd. (Xuchang, 
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Henan, China) and were identified by our laboratory. The 
herbarium specimens (no. SYRM-20090818-0090833) were 
deposited in Hubei University of Medicine (Shiyan, Hubei, 
China). The components were concentrated by decocting 
the solution twice in a 10‑fold volume of water at 100˚C 
for 30 min. It was found that 1 g BSHY corresponded with 
1.2 g raw medicinal material. The concentration of icariin, a 
quantity reference compound in the extract, was 7.12 µg/g in 
a previous study (5). Nilestriol tablets were purchased from 
Shanghai Hualian Pharmaceutical Co., Ltd. (Shanghai, China; 
no. 970710). Chloral hydrate (10%) was freshly prepared in the 
laboratory. The E2 kit was purchased from Shenzhen Laerwen 
Bioengineering Technology Co., Ltd. (Shenzhen, Guangdong, 
China) and the IL-6 kit was purchased from Tianjin Jiuding 
Medical Bioengineering Co., Ltd. (Tianjin, China).
Experimental animals. A total of 48 healthy, female 
Sprague-Dawley rats of SPF grade, aged 3 months 
and weighing 215±45 g were provided by the Hubei 
Laboratory Animal Center (Wuhan, Hubei, China; License 
no. SCXK-E2005-0008). The rats were randomly divided 
into six groups: the control group, the model group, the 
nilestriol group, the low-dose BSHY (BSHY-L) group, the 
medium-dose BSHY (BSHY-M) group and the high-dose 
BSHY (BSHY-H) group. All experiments were conducted 
in accordance with the Guidelines for Ethical Conduct in 
the Care and Use of Experimental Animals of the Hubei 
University of Medicine and were approved by the ethics 
committee of the university.
Oophorectomy model establishment. The animal models 
were established as previously described with minor modifi-
cations (6). In the control group, sham surgery was performed 
and only a small piece of fat tissue near the ovary was 
removed. In all other groups, the ovaries were removed. Two 
weeks after the surgery, 11.1, 22.2 and 44.4 g/kg BSHY was 
administered by intragastric infusion to rats in the BSHY-L, 
BSHY-M and BSHY-H treatment groups, respectively, 
whilst nilestriol (0.1 mg/kg) was administered to rats in the 
nilestriol group. The animals in the control and model groups 
underwent intragastric infusions of 10 ml/kg of 0.9% sodium 
chloride (equal volume to the other groups). Treatment was 
performed for 12 weeks and was completed 24 h prior to 
sample collection.
Sampling and detection. Following the drug treatment, 
blood and serum samples were collected from all the rats. 
Serum ALP, E2 and IL-6 levels were determined. The rats 
were sacrificed by cervical dislocation and the left and right 
femurs were collected. Dual energy X-ray absorptiometry 
was used to measure the bone mineral density in the right 
femur. Serial 4-µm sections were cut at the proximal end of 
the left femur and the slices were stained using hematoxylin 
and eosin. The slices were examined using microscopy 
(Olympus BX43, Olympus Co., Tokyo, Japan) and the average 
number of osteoblasts and osteoclasts was determined.
Statistical analysis. All data are expressed as the 
mean ± standard deviation. The SPSS 13.0 software package 
was used for statistical analysis (SPSS, Inc., Chicago, IL, 
Figure 1. Effect of BSHY on serum E2 levels in rats. ΔP<0.05, vs. the control 
group; *P<0.05, vs. the model group. BSHY, Bushen Huayu extract; E2, estra-
diol; BSHY-L, low-dose BSHY; BSHY-M, medium-dose BSHY; BSHY-H, 
high-dose BSHY.
Figure 2. Effect of BSHY on serum IL-6 levels in rats. ΔP<0.05, vs. the con-
trol group; *P<0.05, vs. the model group. BSHY, Bushen Huayu extract; IL-6, 
interleukin-6; BSHY-L, low-dose BSHY; BSHY-M, medium-dose BSHY; 
BSHY-H, high-dose BSHY.
Figure 3. Effect of BSHY on serum ALP levels in rats. ΔP<0.05, vs. the con-
trol group; *P<0.05, vs. the model group. BSHY, Bushen Huayu extract; ALP, 
alkaline phosphatase; BSHY-L, low-dose BSHY; BSHY-M, medium-dose 
BSHY; BSHY-H, high-dose BSHY.
Figure 4. Effect of BSHY on bone density in the bone metaphysis of the 
rat right femur. ΔP<0.05, vs. the control group; *P<0.05, vs. the model 
group. BSHY, Bushen Huayu extract. BSHY-L, low-dose BSHY; BSHY-M, 
medium-dose BSHY; BSHY-H, high-dose BSHY.
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USA). Statistical differences were evaluated using one way 
analysis of variance. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Effect of BSHY on the serum levels of E2 in oophorec‑
tomized rats. The serum E2 levels in the normal, model, 
nilestriol, BSHY-L, BSHY-M and BSHY-H groups were 
20.71±1.08, 14.54±1.61, 19.34±1.59, 16.89±1.71, 17.95±1.40 
and 18.34±1.43 pg/ml, respectively. The serum levels of E2 
in the model group were significantly lower compared with 
the control group (P<0.05). The levels of E2 in the nilestriol 
group were significantly higher compared with the model 
group (P<0.05). Furthermore, compared with the model 
group, the serum levels of E2 in all three BSHY groups were 
significantly elevated (P<0.05), however, the levels remained 
lower than the control group (Fig. 1).
Effect of BSHY on serum IL‑6 levels in oophorectomized rats. 
The serum levels of IL-6 in the normal, model, nilestriol, 
BSHY-L, BSHY-M and BSHY-H groups were 74.2±12.48, 
105.93±16.50, 76.08±15.79, 91.85±14.81, 82.99±15.65 and 
80.54±14.61 pg/ml, respectively. Compared with the control 
group, the serum levels of IL-6 in the model group were 
significantly increased (P<0.05), while the serum IL‑6 levels 
in the BSHY‑L, BSHY‑M and BSHY‑H groups were signifi-
cantly lower compared with the model group (P<0.05; Fig. 2). 
Effect of BSHY on the serum levels of ALP in oophorecto‑
mized rats. The serum ALP levels in rats in the normal, model, 
nilestriol, BSHY-L, BSHY-M and BSHY-H groups were 
159.88±40.44, 299.13±45.79, 147.88±48.14, 197.75±41.74, 
166.63±44.83 and 165.63±44.90 IU/l, respectively. Compared 
with the control group, the serum ALP levels of rats in the 
model group were significantly elevated (P<0.05), while the 
levels of ALP in the three BSHY treatment groups were 
significantly lower compared with the model group (P<0.05). 
However, no significant differences between the three BSHY 
groups and the nilestriol group were identified (P>0.05; 
Fig. 3). 
Effect of BSHY on bone density in the bone metaphysis of the 
rat right femur. The bone density in the metaphysis of the right 
femur in the normal, model, nilestriol, BSHY-L, BSHY-M and 
BSHY-H groups were 0.22±0.016, 0.19±0.011, 0.23±0.016, 
0.20±0.014, 0.22±0.016 and 0.22±0.017 g/cm2, respectively. 
The bone density in the BSHY-L, BSHY-M and BSHY-H 
groups was elevated compared with the model group (P<0.05) 
and no significant differences between the BSHY treatment 
groups were observed (P>0.05; Fig. 4).
Alterations in bone tissue morphology in the proximal end of 
the left femurs of oophorectomized rats. The bone trabeculae 
in the model group were narrower, more lightly stained and 
more damaged arch-shaped connections were observed 
compared with the control group. Bone trabeculae fragments 
were also observed and the number was significantly reduced 
compared with the control group. In addition, the medullary 
cavity was enlarged in the model group and the quantity 
of bone marrow was increased, compared with the control 
group. However, compared with the model group, the bone 
trabeculae in the three BSHY groups and the nilestriol group 
were all wider, and the space and connections were markedly 
increased. Furthermore, the medullary cavity was reduced in 
size (Fig. 5).
Discussion
Postmenopausal osteoporosis is a systematic imbalance, in 
which the speed of bone resorption is greater than that of 
bone formation. This disease is caused by estrogen deficiency 
and results in microarchitectural changes, particularly bone 
remodeling. Certain critical molecules co-ordinate the actions 
of osteoblasts and osteoclasts during bone remodeling (7). As 
a result of estrogen deficiency during bone remodeling osteo-
Figure 5. Effects of BSHY on bone tissue morphology in oophorectomized rats. (A) Control group; (B) model group; (C) nilestriol group; (D) low-dose BSHY 
group; (E) medium-dose BSHY group and (F) high-dose BSHY group. BSHY, Bushen Huayu extract.
OUYANG et al:  EFFECT OF BUSHEN HUAYU EXTRACTS ON OSTEOPOROSIS IN OOPHORECTOMIZED RATS1690
blasts release receptor activator of NF-κB ligand (RANKL), 
a member of the tumor necrosis factor (TNF) family. RANK 
binds to RANKL on osteoclasts, leading to the differentia-
tion, proliferation, multinucleation, activation and survival 
of osteoclasts (8). In addition, osteoblasts release markers, 
including TNF-α and IL-6 (9). IL-6 generation is attenu-
ated by sex hormones (10-12). IL-6 has been demonstrated 
to directly increase the viability of osteoclasts, inhibit their 
apoptosis and increase the length of their life cycle, resulting 
in osteoporosis (13,14). In the present study, BSHY-treated 
rats exhibited significantly elevated levels of E2, whilst levels 
of IL‑6 were significantly downregulated, indicating that 
BSHY may attenuate the alterations induced in oophorecto-
mized rats.
By contrast, ALP is a biomarker for osteoblasts and the 
levels of ALP have been previously demonstrated to increase 
when the level of estrogen increases in osteoblastic cells 
in vitro (9). However, in the present in vivo study, the serum 
levels of ALP in rats treated with BSHY from the three groups 
decreased (P<0.05). This may be due to the fact that half of 
all ALP is formed in the liver and they may cross-react in 
the bone ALP assay. This result is consistent with a previous 
study (15).
BSHY, a Chinese medicinal formulation, has been 
proposed to supplement the kidney system and resolve blood 
stasis. Among its components, Herba Epimedii (termed 
Yinyanghuo in Chinese) and the active ingredient icariin, 
may have a potential role in the prevention and treatment 
of osteoporosis by increasing the mRNA expression levels 
of osteoprotegerin (a TNF-related cytokine), bone morpho-
genetic protein (a promoter of osteogenesis) and collagen I 
(synthesized by active osteoblasts) in oophorectomized 
rats (16), as well as inducing estrogen biosynthesis (17). 
Rhizoma Drynariae (termed Gusuibu in Chinese) may 
enhance the treatment effects on osteoporosis by reducing 
metabolic disorder (18). The anti-osteoporosis mechanisms 
of other traditional Chinese medicines remain to be eluci-
dated. They may have a combined synergistic effect with 
Herba Epimedii and Rhizoma Drynariae to enhance the 
actions and/or reduce the side-effects.
Further studies are required to investigate whether other 
bone resorption and bone formation parameters, including 
RANKL, RANK, tartrate-resistant acid phosphatase, IL-1, 
calcium, osteocalcin, TNF-α and deoxypyridinoline, are also 
involved in BSHY treatment in oophorectomized rats.
In conclusion, in the present study, BSHY extract was 
demonstrated to have a therapeutic effect on osteoporosis 
caused by oophorectomy, and thus may be a potential 
therapeutic treatment for postmenopausal osteoporosis. 
Furthermore, these results suggest that the mechanism by 
which BSHY decreases the serum levels of IL-6 may be by 
regulating E2.
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